

### REMARKS

Claims 9-46 and 53-97 are pending. Applicants elect Group XXXII (claims 66-67) for examination on the merits, with traverse because Group XXXI (claims 66-68) should also be examined in this application. The claims have been amended to facilitate examination. New claims 93-94 should be examined in this application. Applicants reserve the right to prosecute nonelected subject matter in a further patent application.

Claim 66 has been amended to conform with the scope of the elected invention. New dependent claims 93-94 should be examined with claims 66-67 even if the present restriction requirement is maintained.

Original claim 66 recites use of INPROL "and/or" an opiate compound; amended claim 66 and new claim 95 are similarly based on administering at least INPROL (claim 66) and further administering at least an opiate compound (claim 95). New claims 93-94 and 96-97 list specific INPROL peptides; these same peptides are listed in original claims 59 and 61 as examples of INPROL. Thus, no new matter has been added.

Reconsideration of the restriction requirement is requested.

Amended claim 68 and new claims 95-97 are directed to Group XXXI. Claims 66 and 95 are related as subcombination and combination which should be examined in the same application in accordance with M.P.E.P. § 806.05(c). Here, there has been no demonstration of two-way distinctness of Groups I and II as required by the Manual of Patent Examining Procedure.

Furthermore, both the need for compact prosecution and the public interest would be served by examination of claims 66-68 and 93-97 in the same application.


WOLPE et al. – Appln. No. 10/776,172

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

A handwritten signature in black ink, appearing to read 'Gary R. Tanigawa', written over a horizontal line.

Gary R. Tanigawa  
Reg. No. 43,180

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100